Sanofi Has Collaborated With Radiomedix And Orano Med For Alphamedix (212Pb-DOTAMTATE), For Neuroendocrine Tumors, Radiomedix And Orano Med Will Receive An Upfront Payment Of €100M And Up To €220M In Sales Milestones
Portfolio Pulse from Benzinga Newsdesk
Sanofi has entered into a licensing agreement with Radiomedix and Orano Med for the commercialization of AlphaMedix, a treatment for neuroendocrine tumors. Sanofi will handle global commercialization, while Orano Med will manage manufacturing. Radiomedix and Orano Med will receive an upfront payment of €100M and up to €220M in sales milestones.
September 12, 2024 | 8:16 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sanofi has partnered with Radiomedix and Orano Med to commercialize AlphaMedix, a treatment for neuroendocrine tumors. This partnership involves a significant financial commitment and positions Sanofi as a key player in this therapeutic area.
The partnership with Radiomedix and Orano Med for AlphaMedix positions Sanofi to expand its oncology portfolio, potentially leading to significant revenue growth. The upfront payment and sales milestones indicate a strong commitment to this product's success.
CONFIDENCE 95
IMPORTANCE 85
RELEVANCE 90